Susquehanna International Group’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

Susquehanna International Group’s Portfolio KTTAW Stock Details KTTAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,586	Closed	-$247	–	13032
2025 Q3	$247	Buy	+14,586	New	+$242	﹤0.01%	12225
2025 Q2	–	Sell	-10,579	Closed	-$193	–	13243
2025 Q1	$193	Buy	+10,579	New	+$273	﹤0.01%	12356
2022 Q4	–	Sell	-10,653	Closed	-$2K	–	13095
2022 Q3	$2K	Sell	10,653 -3,150	-23%	-$311	﹤0.01%	12951
2022 Q2	$1K	Buy	+13,803	New	+$1.73K	﹤0.01%	12723

Other funds holding KTTAW

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

Susquehanna International Group's KTTAW Position: Q4 2025 in Review

Susquehanna International Group sold out of Pasithea Therapeutics Warrants (KTTAW) in Q4 2025, closing a stake of 14,586 shares — an estimated $247 sold.

Susquehanna International Group first reported a position in KTTAW in Q2 2022 and held it in 4 quarters. The position peaked at $2K in Q3 2022. 4 funds tracked by Wall St. Rank hold KTTAW as of Q4 2025.

Susquehanna International Group reported no remaining Pasithea Therapeutics Warrants position as of Q4 2025 after selling out during the quarter.
Susquehanna International Group sold 14,586 Pasithea Therapeutics Warrants shares in Q4 2025, an estimated $247.
Susquehanna International Group first reported a position in Pasithea Therapeutics Warrants in Q2 2022 and held it in 4 quarters.
Susquehanna International Group's Pasithea Therapeutics Warrants position peaked at $2K in Q3 2022.
4 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q4 2025.

Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.